Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
How to Choose Among Similar CAR-T Therapies?
**How to Choose Among Similar CAR-T Therapies?**
Currently, there are multiple CAR-T products targeting the same antigen available on the market, which can make it difficult for patients to decide which one to choose.
Experts recommend selecting a therapy based on the treatment target. It is generally advisable to prioritize approved products, as they have been validated, providing better assurance of safety and efficacy. For example, CD19-targeting CAR-T products are typically preferred over CD22-targeting ones, and BCMA-targeting therapies are favored over GPRC5D-targeting ones.
Additionally, it’s important to consider the origin of the CAR-T cells (such as human-derived vs. mouse-derived) and the costimulatory signals used (e.g., 4-1BB vs. CD28). Different conditions may also influence the choice; for instance, lymphoma patients may be more suitable for CD28, while those with acute leukemia might benefit more from 4-1BB.
In the end, patients are advised to make an informed decision based on their medical history and the guidance of their doctors.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
**Patient Story – Oleg’s Cancer Journey:**
Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease relapsed, with several enlarged lymph nodes appearing in his abdomen and other areas. Faced with this resurgence, Oleg was determined not to give up and decided to seek new treatment options to improve his quality of life.
**Tailor-Made CAR-T Treatment Plan:**
After extensive research, Oleg contacted us and connected with lymphoma experts from our Advanced Medicine in China team. Through video consultations and detailed discussions, he decided to pursue CAR-T cell therapy. With confidence in the potential of Chinese CAR-T therapy, Oleg and his family traveled thousands of miles to China to begin his CAR-T treatment journey.
Given Oleg’s high tumor burden and relapse after chemotherapy, the Chinese medical team customized a bridging therapy for him, combining targeted drugs with low-dose radiotherapy to reduce the tumor burden and improve the immune environment. Special care was taken when designing the radiotherapy plan, as Oleg still had fertility concerns. The team created a personalized treatment plan that balanced safety and effectiveness. During the treatment process, Oleg experienced almost no significant side effects, demonstrating excellent treatment compliance and tolerance. He maintained a strong relationship of trust and communication with the medical team.
**Complete CR – A New Life After Treatment**
Oleg’s CAR-T cell infusion process went smoothly. Despite a history of migraines, he only experienced mild headaches and low-grade fever after the treatment. Under the meticulous care of the treatment team, the CAR-T cells demonstrated strong anti-tumor effects, with minimal side effects. For a patient with a high tumor burden, he only developed grade 1 cytokine release syndrome (CRS), and his blood counts began to recover about a week after the infusion. Overall, he remained in good condition.
Fifteen days after the CAR-T infusion, an abdominal ultrasound showed significant shrinkage of the enlarged lymph nodes. Three months later, a PET-CT scan brought even more surprising news—Oleg’s tumors had completely disappeared, and his response was evaluated as a complete remission (CR). This meant that Oleg had beaten cancer!
Today, Oleg is doing better and better, running daily. He is especially grateful for the support and care provided by the Advanced Medicine in China team and the Chinese experts. Despite being far from home, he never felt inconvenienced during his treatment in China. The doctors and nurses not only communicated with him patiently but also provided significant help in his daily life.
**Why Choose CAR-T Treatment in China?**
CAR-T therapy has shown remarkable efficacy in treating relapsed and refractory follicular lymphoma, with clinical data showing an objective response rate (ORR) of over 90% and a median duration of response exceeding three years! Oleg’s case is a testament to China’s advanced medical technology. Traditional chemotherapy tends to lose effectiveness after repeated treatments, while CAR-T therapy offers the possibility of curing diseases like follicular lymphoma, which were previously considered incurable.
For patients like Oleg, who seek a high-quality life, China’s CAR-T therapy is bringing new hope. 
**World-Class – China’s CAR-T Indications and Beyond**
Today, China’s CAR-T is not only actively involved in global research but is also leading many developments in the CAR-T field. For patients like Oleg with follicular lymphoma, only China and the U.S. have approved CAR-T products targeting this condition. However, China’s CR rate is notably higher.
Currently, China offers the most extensive range of CAR-T indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for first-line, second-line, or third-line treatment failures or relapse; relapsed follicular lymphoma (FL) after second-line treatment; mantle cell lymphoma (MCL) with multiple treatment failures; unspecified DLBCL; large B-cell lymphoma transformed from FL; primary mediastinal large B-cell lymphoma; and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #AdvancedMedicineInChina #Lymphoma #FollicularLymphoma #CancerRemission #MedicalTourism #ChinaCare #HealingJourney #CancerFree #Immunotherapy #GlobalHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**
**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**
Multiple Myeloma
#MultipleMyeloma #CARTtherapy #BloodCancer #CompleteRemission #CART
Multiple Myeloma (MM) is a malignant blood disorder characterized by abnormal proliferation of plasma cells, which causes damage to vital organs. Patients with high-risk cytogenetic abnormalities like 17p deletion, t(4;14) translocation, and t(14;16) translocation face an even worse prognosis. While new drugs like proteasome inhibitors and autologous stem cell transplantation have improved MM treatment outcomes, relapsed/refractory multiple myeloma (RRMM) continues to be a challenge due to its aggressive nature and tendency to relapse. Despite the use of traditional therapies, many patients either fail to respond or cannot tolerate further treatment due to underlying health issues.
CAR-T cell therapy, a novel immunotherapy that re-engineers the patient’s own T cells to attack cancer cells, has shown remarkable results in RRMM patients. It offers an alternative for patients who have poor tolerance to conventional treatments, presenting a safer and more effective option. In particular, Equecabtagene Autoleucel, a CAR-T therapy targeting the BCMA antigen on myeloma cells, has demonstrated success in treating patients unresponsive to frontline therapies.
### Case Study: High-Risk MM Patient Achieves Complete Remission
A 45-year-old male patient diagnosed with high-risk multiple myeloma in June 2023 sought further treatment at our hospital after failing to respond to chemotherapy. He had a history of coronary artery disease, diabetes, hypertension, and kidney artery stenosis, making traditional therapies less effective and risky.
Upon evaluation, the patient’s tests indicated κ-type M protein and abnormal free light chains (FLC-κ of 2410.5mg/L). Imaging scans revealed extensive bone damage caused by multiple myeloma. Genetic testing showed high-risk markers including 17p deletion and 1q21 amplification, further complicating his prognosis.
Given his high-risk status and poor response to standard treatments, the medical team decided to proceed with CAR-T cell therapy using Equecabtagene Autoleucel. After a smooth cell collection and lymphodepletion process, the patient received CAR-T infusion on November 15, 2023.
### Treatment Outcome and Safety
Eight days after infusion, the patient developed a mild fever, indicating cytokine release syndrome (CRS), which was effectively managed with symptomatic treatment. Despite mild kidney dysfunction and temporary blood cell reductions, no severe side effects or neurotoxicities occurred. By day 42, the patient developed a lung infection, which was treated with antibiotics, leading to a full recovery.
At the one-month follow-up, flow cytometry showed no minimal residual disease (MRD), confirming the patient had achieved complete remission (CR) with MRD negativity. This outcome was particularly significant considering the patient’s failure to respond to previous treatments.
### A Promising Future for High-Risk MM Patients
This case highlights the potential of CAR-T cell therapy, particularly Equecabtagene Autoleucel, in achieving deep remission for high-risk multiple myeloma patients who fail to respond to conventional therapies. With ongoing advancements in biomedical technology and immunotherapy, CAR-T treatments offer hope for RRMM patients, providing longer disease-free survival and improved quality of life.
🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#ChinaMedicalAdvances #InnovativeTreatments #Immunotherapy #EquecabtageneAutoleucel #CancerResearch
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Why More and More Foreigners Are Choosing China for CAR-T Cell Therapy
**Why More and More Foreigners Are Choosing China for CAR-T Cell Therapy**
CAR-T
In recent years, China’s advancements in cell therapy, particularly CAR-T therapy, have been remarkable, attracting numerous international patients seeking treatment. With its cutting-edge technology, reasonable costs, and outstanding efficacy, China has become a preferred destination for cancer patients worldwide. Today, we will explore why an increasing number of foreign patients choose to come to China for cell therapy.
**The Rise of CAR-T Therapy: China’s Advantages**
First, CAR-T therapy is a personalized immunotherapy that specifically targets blood-related cancers such as lymphoma, multiple myeloma, and leukemia. By engineering a patient’s own T-cells to recognize and attack cancer cells, CAR-T therapy has shown significant efficacy, especially in patients with advanced cancer.
China’s advantages in cell therapy can be summarized into three key points:
-
**Technological Expertise**: China has accumulated extensive experience in CAR-T therapy, particularly in top hospitals in major cities like Shanghai and Beijing. These institutions boast world-class medical teams and advanced treatment systems, providing international patients with high-quality treatment plans that ensure global leading outcomes.
-
**Affordable Costs**: While CAR-T therapy can cost millions of dollars in countries like the U.S. and Europe, the treatment in China is much more affordable, usually about one-seventh to one-tenth of the cost in the U.S. This affordability makes China an attractive option for many international patients.
-
**Shorter Waiting Times**: In Western countries, patients often wait several months for CAR-T therapy, whereas in China, many hospitals can complete the entire process — from diagnosis to cell infusion — in just a few weeks. This is crucial for patients with urgent medical needs.
**Real-Life Cases: Why Foreign Patients Choose China**
Several real-life cases clearly demonstrate why international patients are increasingly seeking treatment in China.
– **Ethan from Singapore**
Ethan had been battling cancer for nearly ten years, trying various treatments globally with little success. Eventually, he decided to seek treatment in China. After a thorough evaluation at Jiahui International Hospital in Shanghai, Ethan received a personalized CAR-T therapy plan. Within just four weeks, his cancer cells had significantly decreased, and his health began to improve, along with his weight. Ethan remarked, “The treatment in China is not only effective but also much more affordable than in Singapore.”
– **A Russian Patient’s Story**
Borzinkov, a 70-year-old patient with high-risk advanced multiple myeloma, had experienced multiple treatment failures before learning about China’s CAR-T therapy. He traveled to China for treatment, successfully completed cell collection, and received CAR-T infusion. Just 13 days later, he was discharged, and his follow-up results have been very promising. He chose China not only for the lower costs but also because of the shorter waiting time.
These cases illustrate that international patients in China can receive high-quality, effective treatment at more affordable rates and with faster recovery times. So far, patients from countries like Russia, Singapore, Malaysia, and others have undergone CAR-T therapy in China and achieved significant results, with many experiencing complete remission within months, with no signs of cancer after treatment.
**China’s Leading Position and Future Prospects**
China has already established itself as a global leader in CAR-T therapy, accounting for over 50% of the world’s clinical trials in this field. Chinese researchers and doctors excel not only in the basic research and clinical applications of CAR-T therapy but also in managing side effects such as CRS and neurotoxicity.
In cities like Shanghai, Wuhan, and Beijing, doctors provide cutting-edge treatment to international patients daily, consistently delivering excellent outcomes. As China’s medical system continues to advance, more and more international patients are choosing China as their destination for treatment.
**Conclusion**
The reasons why foreign patients are choosing China for cell therapy are clear: China excels in technology, offers reasonable treatment costs, and delivers outstanding results. As the world becomes more aware of the progress in China’s healthcare system, more patients will seek advanced medical care in China. In particular, China’s breakthroughs in cell therapy will continue to attract cancer patients from across the globe.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can contact us for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CARtherapy #CellTherapy #CancerTreatment #Immunotherapy #HealthcareInnovation #MedicalTourism #ChinaHealthcare #CancerSurvivor #PatientStories #MedicalAdvancements #AffordableHealthcare #PersonalizedMedicine #GlobalHealth #HealthJourney #Oncology #CAR-T
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma
Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma
Multiple Myeloma
Relapsed/refractory multiple myeloma (RRMM) presents a significant challenge worldwide, representing 13% of all blood cancers. Despite advances in treatment, many patients face poor outcomes and limited options. However, a groundbreaking CAR-T therapy, Equecabtagene Autoleucel, has recently demonstrated its life-changing potential in overcoming this medical impasse.
In February 2024, a 70-year-old patient from Kyrgyzstan, diagnosed with multiple myeloma 17 years ago, arrived at a Hospital of Chinese Xi’an seeking relief from severe pain and disease progression. The patient had undergone multiple treatments over the years, including chemotherapy and radiotherapy, but his condition continued to deteriorate with extensive bone destruction and kidney disease caused by the cancer.
Given the severity of his condition and the failure of previous treatments, he was selected for Equecabtagene Autoleucel therapy. After a series of preparatory treatments, the patient received CAR-T cell infusion in April 2024, and the results were remarkable. Within just one month, his myeloma cells were undetectable, and he achieved a complete response (CR) with no signs of minimal residual disease (MRD). The treatment was not only effective but also safe, with only mild side effects such as grade 1 cytokine release syndrome (CRS), which was easily managed.
This case exemplifies the transformative power of Equecabtagene Autoleucel, which has shown a 98.9% overall response rate (ORR) in clinical trials, with a CR rate of over 82%. It offers a beacon of hope for RRMM patients, particularly those who have exhausted conventional treatment options.
As one of China’s premier CAR-T therapies, Equecabtagene Autoleucel is breaking barriers, providing a new lease on life for patients globally. With its impressive safety profile and unparalleled efficacy, it is poised to play a pivotal role in extending survival and improving quality of life for those battling RRMM. This therapy is not only revolutionizing cancer treatment but also proving to be a lifeline for patients who previously faced limited options.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#MultipleMyeloma #CARTTherapy #CancerTreatment #MedicalInnovation #GlobalHealthcare #HopeForPatients #ChinaMedicalBreakthroughs #EquecabtageneAutoleucel #CAR_T #RRMM
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma
After a period of treatment, the Singaporean patient Teresa achieved remarkable results with CAR-T therapy at Jiahui International Hospital in Shanghai. Her condition reached complete remission (CR), and to celebrate this great news, the hospital held a brief yet heartwarming celebration for her.
In the celebratory photos, Teresa, along with Dr. Vicky Lee and her team of doctors and nurses, are all smiles, radiating the joy of victory. The photos not only captured this happiness but also served as a testament to the hard work and professionalism of the medical staff. Every member of Dr. Vicky Lee’s team is a true hero, using their expertise and selfless dedication to help Teresa overcome her illness.
Teresa, filled with emotion, said: “Although the treatment process was tough, I felt immense warmth and support from the doctors and nurses at Jiahui Hospital. Their professionalism and care gave me confidence, which ultimately led to such a successful outcome.”
On the day of her discharge, the medical staff extended their heartfelt blessings to Teresa. The nurses kindly reminded her of the precautions she needed to take after leaving the hospital, ensuring she could maintain good health during her recovery at home. Teresa expressed her gratitude to each member of the medical team, thanking them for the care and support they provided when she needed it most.
Standing at the hospital entrance, Teresa looked back on her treatment journey, filled with gratitude and hope. She knew that it was because of the selfless dedication and outstanding professionalism of these medical professionals that she could embrace health once again and look forward to a new chapter in life.
Teresa’s recovery story is not only a personal victory but also the result of the collective efforts of the entire medical staff at Jiahui Hospital. She is deeply grateful for their hard work and believes that many more patients will find new hope for recovery here in the future.
We will continue to follow the patient’s post-treatment progress and provide updates.
#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
庆祝出院：新生的喜悦 /希望之路 /与癌症抗争 /希望 /CART/多发性骨髓瘤
###庆祝出院：新生的喜悦
经过一段时间的治疗，新加坡患者Teresa在上海嘉会国际医院的CAR-T治疗取得了令人振奋的成果。她的病情完全达到了完全缓解（CR），在这一喜讯的见证下，医院为她举行了一场简短而温馨的庆祝活动。
在庆祝合影中，Teresa与Dr. Vicky Lee及其团队的医生护士们笑容满面，洋溢着胜利的喜悦。照片不仅记录了这份喜悦，也见证了医护人员的辛勤付出和专业精神。Dr. Vicky Lee和团队的每一位成员都是真正的英雄，他们用专业知识和无私奉献帮助Teresa战胜了病魔。
Teresa感慨万千，她说：“这段时间的治疗过程虽然艰辛，但在嘉会医院医生和护士们的悉心照料下，我感受到了无比的温暖与支持。他们的专业和关怀让我充满了信心，最终取得了这样的好结果。”
出院那天，医护人员为Teresa送上了最真挚的祝福。护士们亲切地叮嘱她出院后的注意事项，确保她在回家后的康复过程中能够继续保持良好的健康状态。Teresa感激地与每一位医护人员道别，感谢他们在她最需要的时候给予的关爱和支持。
站在医院门口，Teresa回望这段治疗旅程，心中充满了感激和希望。她知道，正是因为有了这些无私奉献、专业卓越的医护人员，她才能重新拥抱健康，迎接新的生活。
Teresa的康复故事不仅是她个人的胜利，更是嘉会医院全体医护人员共同努力的成果。她深深感谢他们的辛勤付出，并相信未来将会有更多的患者在这里获得新生的希望。
我们将持续关注患者的治疗后续，并跟进报道。
#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Blood Cancer Solution Including leukemia, lymphoma, multiple myeloma, and others.
Blood Cancer Solution
Including leukemia, lymphoma, multiple myeloma, and others.
Blood Cancer
#leukemia #lymphoma #multiplemyeloma
#Hematologic malignancies are a group of malignant diseases originating from hematopoietic cells, often affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic malignancies include leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma, and myeloproliferative neoplasms.
The causes of these diseases are complex, involving genetic mutations, immune abnormalities, radiation exposure, contact with harmful chemicals, infections, and hereditary factors. Additionally, poor lifestyle habits, high levels of stress, and environmental factors can also increase the risk of developing these conditions.
With an aging population and advancements in medical technology, the incidence of hematologic malignancies has been rising globally. In China, the incidence and mortality rates of leukemia and lymphoma are now among the top ranks of all malignancies.
However, hematologic malignancies are not incurable. In recent years, the treatment methods for these diseases have seen significant progress. From traditional combination chemotherapy and radiotherapy to hematopoietic stem cell transplantation, monoclonal antibody therapy, antibody-drug conjugates, small molecule targeted therapies, and the latest immunotherapies, treatment options have become increasingly diverse and precise.
Combination chemotherapy remains a primary treatment for many hematologic malignancies, despite its significant side effects. The efficacy of these treatments cannot be ignored. Modern chemotherapy regimens are continually being refined, including the incorporation of new cytotoxic drugs and targeted therapies, as well as the use of monoclonal antibodies. Additionally, the appropriate use of antiemetics, hematopoietic growth factors, and anti-infective agents helps to mitigate adverse effects.
Hematopoietic stem cell transplantation continues to be one of the most effective treatments for certain hematologic malignancies. The development of this treatment in China has been rapid, with 170 registered transplant centers by 2020.
Monoclonal antibodies, often referred to as “biological missiles,” have a high degree of specificity and single biological activity. They have revolutionized the treatment of hematologic malignancies. Antibody-drug conjugates (ADCs) utilize monoclonal antibodies to accurately identify tumor cell markers, guiding the delivery of chemotherapy drugs for targeted treatment.
Small molecule targeted therapies work by interfering with specific genes or proteins to inhibit tumor cell growth and proliferation. Gleevec, the first small molecule targeted therapy, increased the five-year survival rate for chronic myeloid leukemia (CML) patients from 30% to 89%, marking a breakthrough in cancer treatment. Today, there are numerous small molecule targeted drugs available for the treatment of hematologic malignancies, including BCR-ABL inhibitors, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and XPO1 inhibitors, with many more drugs currently in clinical trials expected to become available soon.
Immunotherapy includes immune checkpoint inhibitors (such as PD-1/L1), cancer vaccines, cellular immunotherapies (such as #CART), and nonspecific immunomodulatory treatments. #CARTtherapy, in particular, has gained widespread attention as an emerging curative treatment. This approach involves extracting a patient’s T cells, modifying them outside the body to specifically recognize and attack tumor cells, and then reinfusing the modified T cells into the patient. This therapy has been successfully applied to various hematologic malignancies, including acute lymphoblastic leukemia, lymphomas, and multiple myeloma. The first patient treated with CAR-T therapy has been disease-free for 11 years.
In recent years, China has made significant advances in the treatment of hematologic malignancies. The establishment of the “Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma” and the presentation by Professor Huang He at the 2024 #EHA conference on targeting CD7 universal CAR-T therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) have shown remarkable efficacy and safety. Additionally, exciting new data from the 2024 American Society of Clinical Oncology (#ASCO) annual meeting highlighted the efficacy of Relma-cel in treating relapsed/refractory large B-cell lymphoma (R/R LBCL), with a four-year overall survival rate (#OS) of 66.7%. Particularly noteworthy is the research on multiple myeloma, where the BCMA-targeted CAR-T therapy has demonstrated deep and lasting responses, with a complete response (#CR) rate of 82.4% and a 12-month progression-free survival (#PFS) rate of 85.5%.
With the continuous development of new treatments and the emergence of new drugs, hematologic malignancies in China are no longer considered incurable diseases. Through standardized, individualized, and precise treatments, many patients with hematologic malignancies can achieve long-term disease-free survival, and even a cure, returning to normal work and life. As medicine continues to advance, every life will continue to shine brightly!
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#HematologicMalignancies #LeukemiaAwareness #LymphomaResearch #MultipleMyeloma #BloodCancer #CancerResearch #CAR_Therapy #StemCellTransplant #Immunotherapy #TargetedTherapy #MonoclonalAntibodies #CancerTreatment #MedicalAdvancements #CancerSurvivor #HealthcareInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Light of Hope – The Starting Point for Multiple Myeloma Patients
### Light of Hope – The Starting Point for Multiple Myeloma Patients
Ms. Teresa sat in the comfortable seat of the apheresis room, watching the nurse gently insert the needle into her arm to draw the precious white blood cell samples. These white blood cells would become the core material for CAR-T therapy, engineered and then reintroduced into her body to become a powerful force against cancer.
In the operating room, machines hummed softly, precisely separating the T cells from Teresa’s body. These cells, which had faithfully performed their duty of protecting her body, would now be re-educated to become a precise strike team against cancer cells. Teresa closed her eyes and silently prayed that this apheresis would infuse her body with the strength to drive the disease out of her life.
The apheresis process lasted several hours, with medical staff carefully monitoring each step to ensure enough high-quality cells were collected. The extraction of these cells was not only a technical challenge but also a stringent test of the medical team’s professional capabilities.
After the apheresis was completed, Teresa felt somewhat relieved. She knew this was just the first step in a long treatment journey, but it was also an important starting point filled with hope. In the apheresis room, she felt the warmth and professionalism of the medical team, which filled her with confidence and hope for the future treatment.
Back in her ward, Teresa gently closed her eyes as she lay on the bed. She pondered how the coming days would unfold, hoping that this apheresis would bring her the strength to overcome the disease and regain her health.
Apheresis, as the first step of the treatment journey, marked a new chapter in Teresa’s brave fight against cancer and ignited a flame of hope for her future recovery.
#ThePathOfHope #FightingCancer #JourneyOfCARTTherapy #TogetherWithTongji #FullyHumanCART #HopeWithFUCASO #EquecelApproval #HealthReborn #UnitedInPrayer #MultipleMyeloma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease
### Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease
RRMM Patients
In December 2019, a man in his 50s was diagnosed with multiple myeloma (MM) at a hospital in Shenzhen, China. The patient had high-risk cytogenetic abnormalities (17p deletion) and underwent various treatments over more than three years, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies. Despite these treatments, the patient experienced a second relapse. This relapse was characterized by a P53 gene mutation and liver extramedullary invasion, classifying it as an ultra-high-risk situation. Although the patient initially refused an autologous stem cell transplant (ASCT), he was eventually persuaded to collect sufficient stem cells. However, due to concerns about the side effects of high-dose chemotherapy, he opted for CAR-T therapy.
### Personalized Treatment: From ASCT to CAR-T Therapy
Under the care of Professor Chen’s team at the hospital, the patient was evaluated for CAR-T therapy. Despite the risks, he underwent the treatment and showed significant improvement. As of March 2024, he has maintained a complete response (CR) for seven months, with PET/CT scans indicating the disappearance of liver extramedullary disease.
#### Patient Background
– **Age**: 54
– **Initial Symptoms**: Back pain after exercise
– **Diagnosis**: Multiple Myeloma (IgA κ type, DS I A stage, ISS I stage, R-ISS II stage, mSMART high-risk)
### Treatment Journey
– **2019**: Diagnosed with MM; high-risk cytogenetic abnormality (17p deletion)
– **2020-2022**: Treated with PIs, IMiDs, and CD38 monoclonal antibodies
– **Early 2023**: Second relapse with P53 mutation and liver extramedullary disease
– **July 2023**: Stem cell collection for ASCT
– **August 2023**: Initiated CAR-T cell (Equecabtagene Autoleucel) therapy
– **September 2023**: Discharged with strict complete response (sCR)
– **March 2024**: PET/CT scan confirms sustained complete response (CR) with no liver lesions
### Breakthrough Results and Future Prospects
CAR-T therapy has emerged as a promising treatment for relapsed and refractory multiple myeloma (RRMM), especially for patients resistant to conventional therapies. This case highlights the importance of personalized treatment plans, considering disease factors, previous treatment outcomes, and patient preferences. Equecabtagene Autoleucel (IKEA-Lunsay) CAR-T therapy has given this high-risk patient a new lease on life and holds the potential to offer hope to many more MM patients in China.
By showcasing such success stories, we aim to raise awareness about the advancements in CAR-T therapy and its significant impact on improving the quality of life for MM patients. This breakthrough not only marks a significant achievement for the hospital but also signals a new era of hope for countless MM patients.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#MedicalBreakthrough #CARTTherapy #MultipleMyeloma #CancerTreatment #PatientSuccess #HealthcareInnovation #CancerResearch #MMTreatment #LifeSavingTherapies #MedicalAdvancements #HealthcareHeroes #InnovativeMedicine #CancerCare #HopeForMM #CancerAwareness
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients:
What other treatment options are available for patients with relapsed Multiple Myeloma?
How effective is the new drug treatment for the first relapse of Multiple Myeloma?
What treatment options are available for initial relapse of multiple myeloma?
What are the treatment goals for Relapsed/Refractory Multiple Myeloma (RRMM)?
What treatment strategy should be adopted for RRMM in order to achieve maximum relief?
For Relapsed/Refractory Multiple Myeloma, what are the Grades of Response?
Expert Introduction
👩🔬Zhuang Junling
Associate Chief Physician Department of Hematology
Peking Union Medical College Hospital
Published over 50 papers in journals such as Blood, Leukemia Research, and others.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CART #Mutiplemyeloma #CARTtherapy #myeloma #leukemia #drug #RRMM #cancer #cancersurvivor #cancerpatient #bloodcancer #tumor #cartcell #cartcelltherapy #cancertreatment #advancedmedicineinchina #hematology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
cancer fight
🌟Mr. C from California, USA
It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.
🌞New treatment method
Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.
🌤Upon arriving in China,
Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.
🔥Hope and Courage
Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.
☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!
⭐️CAR-T therapy
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to:
💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070
✨The Medical Department will contact you as soon as receive the reports.
#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness